Clincal stage biopharmaceutical company Race Oncology (ASX:RAC)  says Tillett will work alongside executive director Dr  Pete  Smith,  to advance the company’s  strategic, clinical and commercialisation plans for its core asset reformulated bisantrene, RC220. Read more here.